The small molecular inhibitor of VEGFR 2- , 3-kinases and the c KIT receptor of the stem cell factor, Sorafenib (BAY 43-9006), exhibits both of these characteristics.
Targeting VEGFR-derived and Raf/Mek/Erk pathways, Sorafenib is an attractive multifunctional agent for the treatment of solid tumors.